Company / Shareholders' Equity
NRX Pharmaceuticals, Inc. Shareholders' Equity History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$23.2M
FY2025
5-year range
-$23.2M / -$11.7M
FY2024-FY2025
Trend
-97.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
NRX Pharmaceuticals, Inc. reports negative total equity of -$23M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$23M in FY2025.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 97.9% year-over-year.
Company context
Key Data Points
- Altman Z-Score -5.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$23.2M | -97.9% |
| FY2024 | -$11.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026